BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

January 08, 2019

A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

Major marketed drugs for HR+/HER2- breast cancer are discussed, including the cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors. Key late-phase pipeline drugs are also covered, with a focus on Novartis’s alpelisib.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Breast Cancer

 Additional Resources:
Back to the top Back to the top